LuPSMA-617 and Pembrolizumab in mCRPC - Summary - MDSpire
Clinical Guidelines
Feature

LuPSMA-617 and Pembrolizumab in mCRPC

In an Australian phase IB to II study (PRINCE) reported in The Lancet Oncology, Sandhu et al found that the combination of lutetium-177–labeled PSMA-617 (LuPSMA-617) and pembrolizumab was active in pa...

Share

A phase IB to II study published in The Lancet Oncology by Sandhu et al. demonstrates the promising efficacy of the combination of lutetium-177-labeled PSMA-617 (LuPSMA-617) and pembrolizumab in treating patients with metastatic castration-resistant prostate cancer (mCRPC). In this multicenter trial, 37 participants received this treatment regimen over a median follow-up of 30 months, achieving significant PSA reductions. The findings suggest a manageable toxicity profile, potentially offering durable benefits for select patients with mCRPC.

Original Source(s)

LuPSMA-617 and Pembrolizumab in mCRPC

  • by Matthew Stenger

  • April 15, 2026

Related Content

Is Standard of Care Optimal for the Individual Patient?

I am writing this from the hospital waiting room. My father is undergoing an 11-hour surgery to remove his parotid gland and a squamous cell carcinoma that has metastasized from his cheek and invaded ...

From Spectra to Structure: An Interview with Novogaia’s Tess Bevers

Novogaia’s transformer-based model converts untargeted mass spectra into structural predictions for early-stage drug discovery

Mass Spec Roundup: From Masterpieces to Microplastics

Advances in imaging, AI, and single-cell analysis reveal hidden chemistry in art, biology, and the environment

  • April 15, 2026

  • 6 min